shigetec live, attenuated, oral vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 16, 2020 (NCT05409196)
Timeline
Indications
Mechanism of action
- Escherichia coliImmunity, active
Escherichia coli immunity, active
- ShigellaImmunity, active
Shigella immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07049159 | Phase 2 | Jun 30, 2025 | Eveliqure Biotechnologies GmbH |
| NCT05987488 | Phase 1 | Sep 30, 2023 | Eveliqure Biotechnologies GmbH |
| NCT05409196 | Phase 1 | Sep 16, 2020 | Eveliqure Biotechnologies GmbH, University of Debrecen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eveliqure Biotechnologies GmbH | For profit | 3 | 3 | 2 | 2020 |
| University of Debrecen | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1